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Abstract
Transfusion related acute lung injury (TRALI) is a
life-threatening complication of transfusion of blood and its
components resembling acute respiratory distress syndrome
(ARDS) or acute lung injury (ALI). TRALI is a particular
form of ARDS that follows blood transfusion and is caused
by donor-derived antibodies present in the transfused
products, reacting with the recipients' blood cells, inducing
release of inflammatory mediators thus compromising lung
functions. Anti-HLA antibodies are the most frequently
indicted inducers in this category. Literature search has not
revealed any documented case of TRALI from Pakistan.
This in no way implies that TRALI is non existent in this
part of the world but rather indicates that many clinicians
may be unaware of the condition or may not recognize
transfusion as the cause and like in other parts of the world,
is almost certainly under-diagnosed.  The lack of agreement
on the definite cellular and molecular mechanisms
underlying the development of TRALI renders the task of
improving the safety of blood transfusion far more complex
and potentially quite expensive. This review discusses the
modern concepts of pathogenesis of TRALI along with its
clinicopathological manifestations and management with
the aim to improve awareness of our clinicians towards this
dreadful and potentially fatal condition.
Introduction
Transfusion Related Acute Lung Injury is probably
an under-diagnosed and underreported condition.1 Non
cardiogenic pulmonary oedema following blood transfusion
was first described by Barnard in 1951.2 However, not much
was known about the condition until 1985, when Popovsky
et al documented acute respiratory distress syndrome
following blood transfusions as a distinct clinical entity and
coined the term transfusion related acute lung injury
(TRALI), which they described in the order of 1 per 5000.3
Since then its recognition has been variable in various
studies ranging from as frequently as 1/300 transfusions of
red blood cell derivatives4 to as low as 1/1323 in a recent
study.5 Recently, it has been recognized as the most
common cause of transfusion related morbidity and
fatalities.6 This might be the result of global increased
awareness for TRALI amongst clinicians. However, only
one case has been reported from the South East Asian region
which is from India.7
Pathogenesis of TRALI: Current concepts:
All blood components have been implicated in the
production of TRALI, but whole blood-derived platelet
concentrates have been frequently implicated.8 Other
components include FFP, Packed RBCs, whole blood,
apheresis platelets concentrates, granulocytes,
cryoprecipitate and IVIG, and even autologous stem cell
transplantation in decreasing order of frequency.9 There has
also been a case report of TRALI occurring after autologous
blood transfusion10 and also one occurring after infusion of
leukocyte depleted blood in a four-year old child.11 Even
small volumes of plasma (<60 ml) are sufficient to trigger
the reaction12 and its likelihood increases if blood is donated
by multiparous females.13 It has also been shown that
haematologic malignancies or underlying cardiac disease
make the patients at increasing risk of developing TRALI.14
Although TRALI develops within six hours of
transfusion,3 most occurrences take place during transfusion
or within the first one to two hours after it. The pathogenesis
of TRALI is complex and there is lack of agreement on any
one hypothesis. It can result from both immune mechanisms
such as donor derived anti HLA and granulocyte antibodies
(HNA) against recipient's white cells15 or may be non-
immune resulting from neutrophil priming agents such as
lysophosphotadylcholines and proteins like CD40 ligand
which are abundant in stored cellular blood components.16-
18 A 2-event model for the pathogenesis of TRALI has been
proposed: According to this, 2 distinct events are necessary
before the patient is at risk for the development of TRALI.
The first event (e.g., recent surgery, severe infection, or
traumatic injury) causes priming of polymorphonuclear
cells (PMNs) and activation of pulmonary endothelial cells.
This results in the pulmonary sequestration of PMNs. The
second event is the transfusion of biologically active
mediators (Anti-HLA antibodies, Anti-granulocyte
antibodies) present in stored blood components. These
biologically active mediators are able to activate the primed
adherent PMNs, resulting in pulmonary endothelial
damage, capillary leak, and further injuries similar to
ARDS.8 These biologically active agents are probably not
present in the initial phases of storage, but develop over
time.16 Thus, blood components with longer storage times
may be more likely to be associated with TRALI. It should
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be appreciated that the lungs are the main organs affected by
the disorder. This is perhaps because of unique pulmonary
microvasculature which allows 25% of all blood neutrophils
to be sequestered even under physiological conditions.19
In addition to donor antibodies against recipient
antigens on the surfaces of leukocytes, the infusion of donor
leukocytes into recipients having antibodies directed against
donor leukocytes has also been hypothesized.20 Although
neutrophils are the centre of attraction in pathogenesis of
TRALI, yet it has also been reported in neutropenic
patients,21 though very rarely. In these patients, the infusion
of vascular endothelial growth Factor (VGEF), an effective
permeability increasing factor has been implied. More
research is needed to explore if neutropenia is protective
against TRALI. 
Clinical and laboratory diagnosis of TRALI:
Detection of TRALI in a patient is a diagnostic
dilemma and medical personnel should apprehend this new
onset of acute lung injury (ALI) developing during or within
6 hours of blood transfusion in the absence of other cause of
lung injury like shock, septicaemia and aspiration. Criteria
for the clinical diagnosis of TRALI have been defined22,23
and include rapid onset of tachypnoea, cyanosis, dyspnoea,
and fever with and without hypotension.  Hypertension has
also been reported by few. Hypoxaemia (PaO2/FiO2 < 300
mmHg or pO2 <90 % at room air in the absence of impaired
left ventricular function) and bilateral lung infiltrates in the
chest radiograph are the hallmark of the disorder. It is also
important to determine that pulmonary oedema is not due to
cardiac disease or volume overload. Also, TRALI needs to
be distinguished from anaphylactic transfusion reactions,1
and transfusion related circulatory overload.
Various laboratory tests are available for detection of
antibodies (HLA class I and II and HNA) in both patient's
and donor sera. For HLA, enzyme immunoassay and
immunoflourescence are preferred techniques while HNA
antibodies are usually detected by immuno fluorescence but
HNA-3a which is associated with severe TRALI is detected
by agglutination.24 These tests are not standardized and can
be performed only in reference labs. The sophisticated
techniques coupled with their low sensitivity and
specificity25 failed to popularize them for diagnostic
purpose. 
Thus, the diagnosis of TRALI is much the matter of
skilled clinical judgment, expertise and awareness of
clinicians. The significance of the correct diagnosis lies in
the fact that most of the patients recover within 24-48 hours
without permanent sequel.26 However, a variable mortality
of 11% to 45% has been reported.1,3 Concerns have been
raised as being an under diagnosed condition, this fatality
rate might represent the tip of an iceberg.27
Treatment and prevention of TRALI:
The treatment of TRALI is generally supportive and
similar to that for adult respiratory distress syndrome8 and
consists of aggressive respiratory support, including
supplemental oxygen and mechanical ventilation.
Hypovolaemia needs to be corrected and use of diuretics
may be detrimental. There is no role of treatment with
corticosteroids.28 Extra Corporeal Membrane Oxygenation
has been successfully used for a particularly aggressive case
of a four year old.11 Plasmapheresis has been beneficial in
one patient which is logical considering the immune nature
of the disease.29 Additional blood component therapies
should not be withheld if clear indications for transfusion
exist.18 Use of endobronchial adrenaline may be useful as
suggested by animal models.30
The prevention of TRALI remains problematic, and
clear recommendations do not currently exist. Blood donors
with increased levels of particular HLA or granulocyte
antibodies (e.g., multiparous females) have been implicated
as important in the etiology of TRALI, but direct cause and
effect has yet to be proven. Study by Palfi et al in 2001
showed that adverse effects were observed in critically ill
patients when they were transfused with plasma from
multiparious blood donors.31 However as granulocyte and
anti HLA antibodies may or may not be detected in these
donors; the routine use of screening plasma for these
antibodies is not justified.32 Moreover, simple exclusion of
females from donation process will obviously reduce the
donor pool in countries where females generously donate
blood.33 Thus an optimal approach would be to use plasma
from such multiparous donors for preparing protein
derivatives only31 while policy of using male donors for
preparation of plasma seems more logical. For the
prevention of non immune mediated TRALI, it has been
suggested to use either fresh blood or wash the cellular
blood products to remove neutrophil priming agents before
transfusion in recipients who appear to be at risk. But both
these approaches interfere with the prompt issuing of blood
products by the blood bank at the same time increases the
risk of bacterial contamination.15
Future directions:
Although the 2-event model and the various
mechanisms satisfactorily explain most cases of TRALI,
they fail to explain why TRALI occurs with autologous
transfusion, or does not occur when antibodies are
transfused into patients with corresponding antigens. Such
data indicates that TRALI is probably a multifactorial
disorder. Further study is needed to define its etiology,
detect its incidence and risk factors (with special
consideration to our part of the world), pathophysiology,
and optimum treatment. There is also a need to study the
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effects of low-dose epinephrine or methoxamine on the
pulmonary vasculature and control of blood pressure during
and before the occurrence of TRALI initially in animal
models. For this, there is a need to explore the factors that
can predict TRALI, because the mechanisms underlying the
pathogenesis of TRALI are still doubtful which make the
task of improving the safety of blood transfusions extremely
problematic and cost- ineffective. 
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